Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity profile from March 2022 through June 2026 is characterized by a consistent position where current liabilities exceed current assets, as all three primary liquidity ratios remained below the 1.0 threshold throughout the period. A general trend of improvement was observed through 2023, peaking in early 2024, followed by a sharp contraction in liquidity during the latter half of 2024 and a subsequent partial recovery through June 2026.
- Current Ratio
- The current ratio fluctuated between a high of 0.96 (observed in December 2022 and March 2023) and a low of 0.65 in September 2024. A notable decline occurred between March 2024 (0.94) and September 2024 (0.65), marking the period of lowest short-term solvency. Since the beginning of 2025, a gradual recovery trend is evident, with the ratio climbing back to 0.81 by June 2026.
- Quick Ratio
- The quick ratio followed a similar trajectory, peaking at 0.72 in March 2024 before dropping to 0.42 by December 2024. The persistent gap between the current ratio and the quick ratio indicates that a substantial portion of the company's current assets is comprised of inventory. The ratio ended the period at 0.49 in June 2026, reflecting a restricted ability to meet immediate obligations using only highly liquid assets.
- Cash Ratio
- The cash ratio exhibited the highest degree of volatility, rising from 0.19 in March 2022 to a peak of 0.44 in March 2024. This was followed by a steep decline to 0.14 by December 2024 and a further dip to 0.12 in December 2025. The period concluded with a cash ratio of 0.16 in June 2026, suggesting a lean cash position relative to short-term debt.
The synchronized decline across all three metrics during the second half of 2024 suggests a significant increase in short-term obligations or a strategic deployment of liquid capital. While the current ratio shows a modest rebound in 2025 and 2026, the continued low levels of the quick and cash ratios indicate a continuing reliance on inventory liquidation or external financing to manage short-term liquidity needs.
Current Ratio
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Current ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the liquidity position reveals a persistent trend where current liabilities exceed current assets, resulting in a current ratio that remains consistently below 1.00 throughout the observed period. This suggests a structural reliance on operational cash flows or short-term financing to meet immediate obligations.
- Current Ratio Trend Analysis
- Between March 2022 and December 2022, a steady improvement in liquidity is observed, with the current ratio rising from 0.82 to 0.96. This trend of relative stability continued through 2023, where the ratio fluctuated within a range of 0.87 to 0.96.
- A significant deterioration occurred during 2024, marked by a sharp decline from 0.94 in March to a period low of 0.65 in September 2024. The ratio remained depressed at 0.66 in December 2024, representing the most constrained liquidity phase in the reported timeframe.
- From March 2025 through June 2026, a moderate recovery is evident. The ratio climbed from 0.76 in March 2025 to 0.81 by June 2026, although it remained below the peaks observed in 2022 and 2023.
- Analysis of Asset and Liability Drivers
- Current liabilities exhibited a general upward trajectory over the long term, increasing from 32,521 million US$ in March 2022 to 41,642 million US$ by June 2026. This consistent growth in short-term obligations placed sustained pressure on the liquidity ratio.
- Current assets demonstrated significant volatility. A peak of 38,871 million US$ was reached in March 2024, followed by a rapid contraction to 25,582 million US$ by December 2024. The divergence between these falling assets and rising liabilities accounts for the precipitous drop in the current ratio during the 2024 calendar year.
- By the end of the observed period in June 2026, current assets recovered to 33,669 million US$, which, coupled with a slight reduction in current liabilities to 41,642 million US$, contributed to the gradual restoration of the current ratio to 0.81.
Quick Ratio
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||||||
| Total quick assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Quick ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position of the entity shows significant volatility over the analyzed period, characterized by a period of relative improvement followed by a sustained decline in the quick ratio. The ratio remained consistently below 1.00 throughout the entire timeframe, indicating that quick assets were insufficient to cover short-term obligations without the liquidation of inventory.
- Quick Ratio Performance
- The quick ratio exhibited an upward trend from March 2022 (0.52) to a peak of 0.72 in March 2024. However, a sharp contraction occurred thereafter, with the ratio falling to 0.42 by December 2024 and reaching a period low of 0.41 in December 2025. By June 2026, the ratio showed a slight recovery to 0.49, though it remained below the levels observed during the 2022-2023 period.
- Analysis of Quick Assets
- Total quick assets displayed substantial fluctuations, growing from 16,831 million US dollars in March 2022 to a high of 30,016 million US dollars in March 2024. Following this peak, quick assets entered a period of volatility and overall decline, ending at 20,393 million US dollars in June 2026.
- Current Liabilities Trends
- Current liabilities followed a consistent long-term upward trajectory. Starting at 32,521 million US dollars in March 2022, obligations increased steadily, surpassing 40,000 million US dollars by March 2024 and peaking at 43,289 million US dollars in December 2025. This expansion of short-term debt acted as a primary driver in the compression of the liquidity ratio.
- Liquidity Divergence
- A notable divergence is observed between March 2024 and December 2025, where a decrease in quick assets coincided with an increase in current liabilities. This dual pressure resulted in a marked reduction of the immediate liquidity buffer, shifting the quick ratio from its maximum value of 0.72 to its minimum value of 0.41.
Cash Ratio
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||||||
| Total cash assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Cash ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity profile from March 2022 to June 2026 is characterized by significant volatility in cash reserves and a general expansion of current obligations, leading to a fluctuating cash ratio that peaked in early 2024 before entering a period of contraction.
- Cash Ratio Trajectory
- A growth phase is observed between March 2022 and March 2024, during which the cash ratio increased from 0.19 to a peak of 0.44. This improvement was primarily supported by a substantial rise in total cash assets, which reached a high of $18.067 billion in March 2024. Following this peak, a consistent downward trend occurred, with the ratio falling to a low of 0.12 by December 2025.
- Analysis of Current Liabilities
- Current liabilities exhibited a steady long-term increase, rising from $32.521 billion in March 2022 to a peak of $43.289 billion in December 2025. The growth of these short-term obligations, particularly during 2024 and 2025, exerted downward pressure on the cash ratio, as the increase in liabilities outpaced the accumulation of cash assets.
- Cash Asset Volatility
- Total cash assets demonstrated a cyclical pattern of accumulation and depletion. Significant spikes were noted in September 2022 ($11.832 billion), September 2023 ($13.287 billion), and March 2024 ($18.067 billion). This was followed by a period of diminished liquidity where assets dropped to $5.175 billion by March 2025. A partial recovery was observed in March 2026 with cash assets rising to $9.391 billion, though this was not sustained into June 2026.
- Recent Liquidity Position
- The most recent data indicates a stabilization at lower levels compared to the 2023-2024 period. While the cash ratio saw a brief uptick to 0.22 in March 2026, it returned to 0.16 by June 2026, suggesting that the company is maintaining a leaner cash position relative to its current liabilities than it did during the first half of the analyzed timeframe.